Company intelligence / Profile preview

ScarX Therapeutics

Toronto, Ontario, Canadacrunchbase.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

ScarX Therapeutics has developed SCX‑001, a topical cream formulation of nefopam intended to reduce post-surgical skin scarring. The company completed a Phase 1 clinical trial evaluating safety and tolerability in healthy volunteers with induced dermal wounds. Exploratory assessments for efficacy were included. No published results indicate advancement beyond this stage as of the most recent updates

Therapeutic areas: Dermatology
Modalities: Small molecules (topical cream formulation of nefopam)
Industry: Biotech

Partnerships

MaRS Innovation/The Hospital for Sick Children (founding partners and licensors)

Beyond the preview

Go deeper on ScarX Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ScarX Therapeutics.

Explore the full profile